For anyone in Kóny searching for CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor controls every quality variable. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Kóny researcher needs before placing a first order.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Kóny comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors requires starting from the COA: locate the batch-specific certificate prior to buying, not after. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Warning signs in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that do not include endotoxin results. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Kóny
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Proper handling of CJC-1295 requires sterile reconstitution technique — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. The main safety concern arising from sourcing in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the specific protection against this risk. PubMed are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
